IAA Journal of Applied Sciences 14(1):30-35, 2026. www.iaajournals.org
©IAAJOURNALS ISSN: 2636-7246
https://doi.org/10.59298/IAAJAS/2026/1413035 IAAJAS: 141000

The Interplay of Insulin Resistance, Inflammation, and Antioxidant Depletion in Diabetes: A Comprehensive Review

Chelimo Faith Rebecca

Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: rebecca.chelimo@studwc.kiu.ac.ug

ABSTRACT

Diabetes mellitus arises through a multifaceted network of metabolic derangements, prominently featuring insulin resistance, chronic inflammation, and oxidative stress. These three processes do not occur in isolation; rather, they form a self-reinforcing triad that accelerates metabolic dysfunction and tissue injury. Insulin resistance increases glucose and lipid flux into susceptible tissues, driving mitochondrial overload and excessive generation of reactive oxygen species (ROS). Concurrently, hyperglycaemia and dyslipidaemia activate innate immune sensors, promoting the release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. These inflammatory mediators further impair insulin receptor signaling, creating a vicious cycle that sustains metabolic impairment. At the same time, antioxidant defenses—including glutathione, superoxide dismutase, catalase, and peroxiredoxins—become depleted due to chronic oxidative burden and reduced transcriptional activation of protective pathways such as Nrf2. The resulting imbalance intensifies ROS-mediated cellular injury, endothelial dysfunction, β-cell exhaustion, and immunometabolic dysregulation. This review synthesizes current mechanistic insights into the interconnected roles of insulin resistance, inflammation, and antioxidant depletion in type 1 and type 2 diabetes, with emphasis on molecular pathways, clinical implications, and emerging therapeutic targets. Understanding these intertwined processes is essential for designing integrated interventions aimed at preventing disease progression and reducing complications.

Keywords: insulin resistance, inflammation, oxidative stress, antioxidant depletion, diabetes mellitus

INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia arising from impaired insulin secretion, insulin resistance, or a combination of both[1]. While historically conceptualized primarily as a disease of glucose dysregulation, contemporary research highlights diabetes as a systemic immunometabolic condition. Central to its pathophysiology is the convergence of oxidative stress, chronic low-grade inflammation, and metabolic inflexibility, each reinforcing and amplifying the other[2]. Hyperglycaemia and elevated circulating lipids overload metabolic pathways, promoting mitochondrial dysfunction and excessive generation of reactive oxygen species[3]. These oxidant species damage lipids, proteins, and nucleic acids, triggering inflammatory pathways and impairing insulin signaling. Simultaneously, immune activation particularly through innate immune receptors such as Toll-like receptors and the NLRP3 inflammasome drives the release of cytokines that inhibit insulin receptor function and accelerate β-cell exhaustion[4]. The progressive depletion of endogenous antioxidant systems, including glutathione, catalase, and superoxide dismutase, further reduces cellular resilience to metabolic stress[5].

Together, these processes form a metabolic-inflammatory-redox axis that plays a decisive role in the initiation, amplification, and long-term progression of both type 1 and type 2 diabetes[6]. Disruption in any single component affects the others, creating a self-propagating cycle of metabolic impairment, tissue injury, endothelial

dysfunction, and eventual multi-organ complications. This review examines the major molecular drivers of insulin resistance, with a focus on how inflammatory signaling and oxidative damage intersect to undermine metabolic control[7]. In addition, it explores how obesity, altered adipokine secretion, ectopic fat deposition, and organelle stress contribute to the loss of insulin sensitivity[8]. A thorough understanding of these interconnected mechanisms is essential for identifying therapeutic strategies capable of restoring metabolic homeostasis and preventing the progression of diabetic complications[9].

2. Mechanisms and Drivers of Insulin Resistance

2.1 Cellular and Molecular Basis

Insulin resistance develops when peripheral tissues such as skeletal muscle, liver, and adipose tissue fail to mount an appropriate metabolic response to circulating insulin[10]. This impairment stems from defects in multiple components of the insulin signaling cascade, including reduced phosphorylation of the insulin receptor, dysfunctional IRS-1 and IRS-2 activity, diminished PI3K stimulation, and inadequate AKT activation. These abnormalities reduce glucose transporter translocation, impair glycogen synthesis, and disrupt lipid metabolism[11]. Several molecular disturbances further weaken insulin signaling. Serine phosphorylation of IRS proteins, driven by inflammatory kinases including JNK, IKKβ, and p38 MAPK, blocks their ability to propagate insulin's metabolic effects. Lipid intermediates such as diacylglycerols and ceramides accumulate in insulin-responsive tissues, activating PKC isoforms that inhibit insulin receptor activity[12]. Mitochondrial dysfunction contributes by elevating ROS generation, which oxidatively damages signaling proteins and interferes with glucose uptake. Endoplasmic reticulum stress, initiated by nutrient overload, activates the unfolded protein response, promoting inflammatory signaling and further aggravating insulin resistance[13].

2.2 Obesity, Adipokine Dysfunction, and Ectopic Fat

Obesity profoundly reshapes adipose tissue biology, shifting it from a metabolically supportive organ to a source of metabolic and inflammatory stress[14]. Altered adipokine secretion is a major contributor: adiponectin levels fall, reducing fatty acid oxidation and weakening antioxidant defenses; leptin levels rise, promoting chronic inflammation; and resistin increases, contributing to hepatic insulin resistance[15]. In addition, ectopic lipid deposition in the liver and skeletal muscle exacerbates insulin resistance by increasing lipotoxic intermediates and promoting mitochondrial overload and oxidative stress[16]. These metabolic derangements collectively reinforce insulin resistance and set the stage for progressive hyperglycaemia.

3. Chronic Inflammation in Diabetes

Chronic, low-grade inflammation is a defining feature of diabetes and plays a central role in the development and worsening of insulin resistance, β-cell dysfunction, and metabolic inflexibility[17]. This inflammatory state arises from a combination of nutrient excess, oxidative stress, dysfunctional adipose tissue biology, and immunometabolic reprogramming. As hyperglycaemia and lipotoxicity persist, immune cells in metabolic tissues undergo activation and phenotypic shifts that perpetuate cytokine release and redox imbalance[18]. Over time, these processes form a feed-forward cycle in which inflammation impairs insulin signaling, while impaired signaling further increases metabolic stress and immune activation.

3.1 Innate Immune Activation

Innate immunity is one of the earliest systems disrupted in diabetes[19]. Hyperglycaemia, elevated fatty acids, and oxidative stress activate pattern-recognition receptors, particularly Toll-like receptors 2 and 4[20]. These receptors detect saturated fatty acids and damage-associated molecular patterns generated by stressed or dying cells. Downstream signaling through NF-κB and MAPKs induces transcription of pro-inflammatory cytokines[21]. The NLRP3 inflammasome is similarly triggered by mitochondrial ROS, ceramide accumulation, and extracellular ATP, resulting in the maturation and secretion of IL-1β and IL-18[22]. In adipose tissue, macrophages shift from an anti-inflammatory M2 phenotype toward a pro-inflammatory M1 state, producing cytokines that interfere with insulin signaling in adipocytes and exacerbate tissue dysfunction.

3.2 Systemic Cytokine Dysregulation

As inflammation spreads, systemic cytokine levels rise, contributing to whole-body metabolic deterioration[23]. TNF-α impairs insulin receptor kinase activity and promotes lipolysis, increasing circulating fatty acids. IL-6 enhances hepatic gluconeogenesis and fosters acute-phase protein production, linking metabolic stress to inflammation[24]. IL-1β disrupts β-cell insulin secretion and accelerates β-cell apoptosis. Together, these cytokines reinforce insulin resistance and hasten progression to symptomatic diabetes.

3.3 Adaptive Immune Contributions

Adaptive immunity also contributes significantly to diabetic inflammation[25]. Th1 and Th17 cells accumulate in adipose tissue and islets, releasing cytokines that worsen local inflammation. Regulatory T cells, which maintain immune tolerance, decline in number or effectiveness, weakening anti-inflammatory control[26]. B-cell activation contributes both autoantibodies and inflammatory cytokines. These adaptive responses interact with innate pathways, sustaining the chronic inflammatory milieu characteristic of diabetes.

4. Oxidative Stress and Antioxidant Depletion

Oxidative stress represents one of the fundamental biochemical abnormalities in diabetes, linking hyperglycaemia, inflammation, and metabolic dysfunction[27]. In the diabetic state, reactive oxygen species accumulate beyond the capacity of endogenous antioxidant defenses, creating an imbalance that disrupts cellular homeostasis. This persistent oxidative burden accelerates the deterioration of insulin signaling, damages pancreatic β-cells, and drives vascular and neurological complications[28]. The interplay between increased ROS production and progressive antioxidant depletion forms a self-sustaining loop that amplifies metabolic injury over time.

4.1 Sources of ROS in Diabetes

Hyperglycaemia initiates excessive ROS generation through several interconnected biochemical pathways[29]. Mitochondrial electron transport chain overload is a primary source: high glucose increases electron donors such as NADH and $FADH_2$, driving electron leakage and superoxide formation. NADPH oxidase enzymes contribute additional ROS, particularly in endothelial cells, macrophages, and adipocytes, where NOX1, NOX2, and NOX4 are upregulated by hyperglycaemia and inflammatory cytokines[30]. Xanthine oxidase and uncoupled nitric oxide synthase further amplify oxidative stress, shifting nitric oxide production toward superoxide and peroxynitrite formation. Advanced glycation end products interact with their receptor RAGE, triggering signaling cascades that enhance intracellular ROS production and perpetuate inflammation[31]. Collectively, these pathways create a sustained pro-oxidant environment harmful to both metabolic and immune functions.

4.2 Impairment of Antioxidant Systems

As oxidative stress intensifies, endogenous antioxidant systems become progressively impaired. Glutathione, the most abundant intracellular antioxidant, is depleted due to increased utilization and reduced synthesis linked to limited NADPH availability[32]. Key enzymatic defenses, including superoxide dismutase and catalase, show reduced activity in diabetic tissues, undermining the detoxification of superoxide and hydrogen peroxide. Nrf2 signaling, which orchestrates the transcription of antioxidant and cytoprotective genes, becomes suppressed by chronic inflammation, lipid peroxidation products, and mitochondrial dysfunction[33]. This decline in antioxidant capacity weakens cellular resilience, exacerbates β-cell vulnerability to oxidative injury, and accelerates microvascular and macrovascular pathology.

Future Directions

Future research in diabetes should aim to unravel the complex interactions between insulin resistance, inflammation, and oxidative stress with greater mechanistic precision[34]. One important direction is the development of precision medicine frameworks that incorporate genomic, metabolomic, and inflammatory biomarkers to tailor therapeutic strategies to individual patients. Such personalized approaches would enable targeted use of anti-inflammatory agents, antioxidant therapies, or metabolic modulators based on each patient's dominant pathological drivers[35]. Another promising frontier involves targeting key metabolic-inflammatory nodes that lie at the intersection of these pathways. Molecules such as JNK, NLRP3, and specific NOX isoforms represent strategic intervention points capable of simultaneously reducing inflammation and oxidative stress while improving insulin sensitivity[36]. Modulation of these pathways could provide more unified and effective treatments compared with traditional glucose-lowering therapies. Restoring mitochondrial health also represents a critical avenue, as mitochondrial dysfunction is a major source of ROS and metabolic inflexibility[37]. Enhancing mitochondrial biogenesis, supporting mitochondrial DNA stability, and promoting mitophagy may together reduce oxidative burden and safeguard insulin signaling.

Finally, integrated lifestyle–pharmacologic strategies remain essential. Combining structured exercise, anti-inflammatory nutrition, weight management, and modern pharmacotherapy may offer the most sustainable means of breaking the cycle of oxidative stress, chronic inflammation, and insulin resistance that drives diabetes progression.

CONCLUSION

Insulin resistance, chronic inflammation, and antioxidant depletion constitute a tightly interconnected triad that underlies the onset, progression, and complications of diabetes. Each component amplifies the others through overlapping metabolic, redox, and immunological pathways, resulting in heightened oxidative stress, impaired insulin signaling, β-cell dysfunction, and widespread tissue injury. Interventions targeting a single pathway often provide limited or transient benefit because the remaining mechanisms continue to propagate metabolic dysfunction. By contrast, integrated therapeutic strategies that simultaneously address insulin resistance, inflammatory activation, and redox imbalance are more likely to restore metabolic homeostasis, protect organ function, and prevent long-term diabetic complications. A comprehensive mechanistic understanding of this triad is essential for the development of personalized treatments and preventive measures that can effectively interrupt these self-reinforcing pathogenic cycles.

REFERENCES

1. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393
2. Ugwu, O.P.C.,Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
3. Godfrey Ogochukwu Ezema, Ndukaku Yusuf Omeh, Egba Simeon Ikechukwu, Ejiofor C Agbo, Adachukwu Ada Ikeyiand Emmanuel Ifeanyi Obeagu. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia (2023) Asian Journal of Dental and Health Sciences 2023; 3(2):32-36
4. Ogugua, Victor N., Njoku, Obioma U., Egba, Simeon I., Uroko, Robert I and Ignatius Glory. In vitro study of nutritional and antioxidant properties of methanol extract of *Nauclea latifolia* root bark. Biomedical Research, 2018; 29(21): 3766-3773
5. Ochulor Okechukwu C., Njoku Obioma U., Uroko Robert I and Egba Simeon I**.** Nutritional composition of *Jatropha tanjorensis* leaves and effects of its aqueous extract on carbon tetrachloride induced oxidative stress in male Wistar albino rats. Biomedical Research 2018; 29(19): 3569-3576
6. Caturano A, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, Iadicicco I, Donnarumma M, Galiero R, Acierno C, et al. Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications. Antioxidants. 2025; 14(1):72. https://doi.org/10.3390/antiox14010072
7. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014 Apr 11;15(4):6184-223. doi: 10.3390/ijms15046184. PMID: 24733068; PMCID: PMC4013623.
8. Choi W, Woo GH, Kwon T-H, Jeon J-H. Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction. International Journal of Molecular Sciences. 2025; 26(19):9715. https://doi.org/10.3390/ijms26199715
9. Rabiee A, Hossain MA, Poojari A. Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 2025; 13(10):2376. https://doi.org/10.3390/biomedicines13102376
10. Sun M, Zhang Z, Xie J, Yu J, Xiong S, Xiang F, Ma X, Yang C, Lin L. Research Progress on the Mechanism for Improving Glucose and Lipid Metabolism Disorders Using Phenolic Acid Components from Medicinal and Edible Homologous Plants. Molecules. 2024; 29(20):4790. https://doi.org/10.3390/molecules29204790
11. Kanungo S, Wells K, Tribett T, El-Gharbawy A. Glycogen metabolism and glycogen storage disorders. Ann Transl Med. 2018 Dec;6(24):474. doi: 10.21037/atm.2018.10.59. PMID: 30740405; PMCID: PMC6331362.
12. Amen OM, Sarker SD, Ghildyal R, Arya A. Endoplasmic Reticulum Stress Activates Unfolded Protein Response Signaling and Mediates Inflammation, Obesity, and Cardiac Dysfunction: Therapeutic and Molecular Approach. Front Pharmacol. 2019 Sep 10;10:977. doi: 10.3389/fphar.2019.00977. PMID: 31551782; PMCID: PMC6747043.
13. Izah, S.C., Betiang, P.A., Ugwu, O.P.C., Ainebyoona, C., Uti, D.E., Echegu, D.A. The Ketogenic Diet in Obesity Management: Friend or Foe?. *Cell Biochem Biophys* (2025). https://doi.org/10.1007/s12013-025-01878-0
14. Uti, D. E., Atangwho, I. J., Omang, W. A., Alum, E. U., Obeten, U. N., Udeozor, P.A., Agada, S. A., Bawa, I., Ogbu, C. O. Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine, Volume 54, 2025,100585. https://doi.org/10.1016/j.obmed.2025.100585.
15. Alum, E. U. Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obesity Medicine. 2025; 55,100610. https://doi.org/10.1016/j.obmed.2025.100610
16. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.A. Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine, 2025; 100622. https://doi.org/10.1016/j.obmed.2025.100622
17. Alexander M, Cho E, Gliozheni E, Salem Y, Cheung J, Ichii H. Pathology of Diabetes-Induced Immune Dysfunction. International Journal of Molecular Sciences. 2024; 25(13):7105. https://doi.org/10.3390/ijms25137105
18. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune

System. Curr Diabetes Rev. 2020;16(5):442-449. doi: 10.2174/1573399815666191024085838. PMID: 31657690; PMCID: PMC7475801.
19. Rajamani U, Jialal I. Hyperglycemia induces Toll-like receptor-2 and -4 expression and activity in human microvascular retinal endothelial cells: implications for diabetic retinopathy. J Diabetes Res. 2014;2014:790902. doi: 10.1155/2014/790902. Epub 2014 Dec 31. Retraction in: J Diabetes Res. 2020 Oct 3;2020:5071954. doi: 10.1155/2020/5071954. Erratum in: J Diabetes Res. 2016;2016:8976945. doi: 10.1155/2016/8976945. PMID: 25610879; PMCID: PMC4293793.
20. Chimaroke Onyeabo, Paul Anyiam Ndubuisi, Anthony Cemaluk Egbuonu, Prince Chimezie Odika, Simeon Ikechukwu Egba, Obedience Okon Nnana, Polycarp Nnacheta Okafor. Natural products-characterized Moringa oleifera leaves methanolic extractand anti-diabetic properties mechanisms of its fractions in streptozotocin-induced diabetic rats The Nigerian Journal of Pharmacy, 2022; 56(1):18-29
21. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328. doi: 10.3390/ijms20133328. PMID: 31284572; PMCID: PMC6651423.
22. Guo K, Zeng X, Liu X, He P, Zhang Z, Yang Q, Wang L, Jing L. Lifestyle deterioration linked to elevated inflammatory cytokines over a two-month follow-up. Sci Rep. 2024 Sep 13;14(1):21381. doi: 10.1038/s41598-024-69967-3. PMID: 39271678; PMCID: PMC11399254.
23. Sartori AC, Vance DE, Slater LZ, Crowe M. The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs. 2012 Aug;44(4):206-17. doi: 10.1097/JNN.0b013e3182527690. PMID: 22743812; PMCID: PMC3390758.
24. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. J Diabetes Res. 2018 Nov 8;2018:7457269. doi: 10.1155/2018/7457269. PMID: 30533447; PMCID: PMC6250017.
25. Xue M, Mao X, Chen M, Yin W, Yuan S, Liu Q. The Role of Adaptive Immunity in Diabetic Retinopathy. Journal of Clinical Medicine. 2022; 11(21):6499. https://doi.org/10.3390/jcm11216499
26. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
27. Ikpozu EN, Offor CE, Igwenyi, I.O, Ibiam, U.A., Obaroh, I.O. et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251334726
28. Eze Chukwuka W., Egba Simeon, Nweze Emeka I., Ezeh Richard C. and Ugwudike Patrick. Ameliorative Effects of *Allium cepa* and *Allium sativum* on Diabetes Mellitus and Dyslipidemia in Alloxan-induced Diabetic *Rattus novergicus*. *Trends Applied Sci Res*, 2020; 15(2): 145-150
29. Uhuo E N, Egba S I, Nwuke P C, Obike C A and Kelechi G K. Antioxidative properties of Adansonia digitata L. (baobab) leaf extractexert protective effect on doxorubicin induced cardiac toxicity in Wistar rats. Clinical Nutrition Open Science 2022; 45:3-16
30. Krishnamoorthy, R., Gatasheh, M. K., Subbarayan, S., Vijayalakshmi, P., Uti, D. E. Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Natural Product Communications. 2024;19(12). doi:10.1177/1934578X241299279
31. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009 Feb-Apr;30(1-2):1-12. doi: 10.1016/j.mam.2008.08.006. Epub 2008 Aug 30. PMID: 18796312; PMCID: PMC2696075.
32. Vázquez-Meza H, Vilchis-Landeros MM, Vázquez-Carrada M, Uribe-Ramírez D, Matuz-Mares D. Cellular Compartmentalization, Glutathione Transport and Its Relevance in Some Pathologies. Antioxidants. 2023; 12(4):834. https://doi.org/10.3390/antiox12040834
33. Tian X, Wang L, Zhong L, Zhang K, Ge X, Luo Z, Zhai X, Liu S. The research progress and future directions in the pathophysiological mechanisms of type 2 diabetes mellitus from the perspective of precision medicine. Front Med (Lausanne). 2025 Mar 5;12:1555077. doi: 10.3389/fmed.2025.1555077. PMID: 40109716; PMCID: PMC11919862.
34. Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J, Franczyk B. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. International Journal of Molecular Sciences. 2025; 26(3):1094. https://doi.org/10.3390/ijms26031094
35. de Deus IJ, Martins-Silva AF, Fagundes MMA, Paula-Gomes S, Silva FGDE, da Cruz LL, de Abreu ARR, de Queiroz KB. Role of NLRP3 inflammasome and oxidative stress in hepatic insulin resistance and the ameliorative effect of phytochemical intervention. Front Pharmacol. 2023 Jun 30;14:1188829. doi:

10.3389/fphar.2023.1188829. PMID: 37456758; PMCID: PMC10347376.

36. Manful CF, Fordjour E, Ikumoinein E, Abbey L, Thomas R. Therapeutic Strategies Targeting Oxidative Stress and Inflammation: A Narrative Review. BioChem. 2025; 5(4):35. https://doi.org/10.3390/biochem5040035

CITE AS: Chelimo Faith Rebecca (2026). The Interplay of Insulin Resistance, Inflammation, and Antioxidant Depletion in Diabetes: A Comprehensive Review. IAA Journal of Applied Sciences 14(1):30-35. https://doi.org/10.59298/IAAJAS/2026/1413035